Due to the known high variability between CF patients and the unicity of each patient’s microbiota (e.g., specific mutations in the CFTR gene and the individual patient treatment regimens), the analysis of a larger sample size may have revealed additional microorganisms/functions. This evidence concerns the gene CFTR and cystic fibrosis.